LabStyle Innovations, Creator of Dario™ Diabetes mHealth Solution, to present at the 26th Annual Roth Conference on March 11, 2014

March 6, 2014 6:25 am

President and CEO Erez Rafael to address how mHealth can make life easier for people with diabetes and other chronic diseases

CAESAREA, IsraelMarch 6, 2014 /PRNewswire/ — LabStyle Innovations Corp(OTCQB: DRIO), developer of the Dario™ Diabetes mHealth Solution, today announced that its president and chief executive officer, Mr. Erez Rafael, will be presenting at the 26th Annual Roth Conference.  The presentation is scheduled for Tuesday, March 11, 2014 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) at the Ritz Carlton, Laguna Niguel, California.

Mr. Rafael will discuss how mHealth solutions like Dario™ create the potential to make life easier for people with chronic diseases like diabetes all over the world.

Mr. Rafael will also show a preview of the soon-to-be shipped Dario™ smart meter and present an overview of the company’s recent key achievements and plans for the future.

The presentation will be webcast live and a link to the audio and slides will be found at: For those who are not available to listen to the live broadcast, a replay of the webcast will be available on LabStyle’s website in the Investor Room section:

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dariopersonalized Diabetes mHealth Solution.   Dario received CE mark certification in September 2013 and began a world rollout of the Dario mobile application in select countries in December 2013, with initial launches of the full Dario solution expected in EuropeAustralia and New Zealand during 2014.  LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario Blood Glucose Monitoring System) in December 2013.  LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: www.mydario.comand

Cautionary Note Regarding Forward-Looking Statements

This news release, the presentation referred to herein, and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.




Investor Relations

Brenda Zeitlin

LabStyle Innovations

Book and Company Inc.

1 212 490 9095

972 54 3304831


SOURCE LabStyle Innovations Corp.